Eurizon Capital SGR S.p.A. Invests $28.89 Million in Cencora, Inc. $COR

Eurizon Capital SGR S.p.A. bought a new position in shares of Cencora, Inc. (NYSE:COR) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 85,529 shares of the company’s stock, valued at approximately $28,892,000.

A number of other hedge funds also recently modified their holdings of COR. Oakworth Capital Inc. acquired a new stake in Cencora in the 4th quarter worth about $26,000. Elyxium Wealth LLC acquired a new stake in Cencora in the 4th quarter worth about $27,000. Archer Investment Corp raised its stake in Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares in the last quarter. IAG Wealth Partners LLC acquired a new stake in Cencora in the 3rd quarter worth about $30,000. Finally, Caitlin John LLC acquired a new stake in Cencora in the 3rd quarter worth about $31,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

COR stock opened at $269.21 on Friday. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The firm has a market cap of $52.38 billion, a P/E ratio of 20.65, a P/E/G ratio of 1.24 and a beta of 0.64. The company’s 50-day moving average price is $298.56 and its two-hundred day moving average price is $333.91.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same period in the prior year, the business earned $4.42 earnings per share. Cencora’s quarterly revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its board has approved a stock repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to purchase up to 3.9% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. Cencora’s dividend payout ratio (DPR) is currently 18.40%.

Analysts Set New Price Targets

Several analysts have weighed in on COR shares. Wells Fargo & Company dropped their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research note on Monday, May 11th. William Blair started coverage on shares of Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating for the company. Evercore set a $360.00 price objective on shares of Cencora in a research note on Wednesday, April 8th. Weiss Ratings cut shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 22nd. Finally, Robert W. Baird dropped their price objective on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and a consensus target price of $380.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.